Regorafenib 1st Patient Enrolled in Metastatic Colorectal Cancer Study

Congratulations to Dr Anne Horgan and the all of the team in Waterford Regional Hospital on the accrual of the first ICORG patient to this important study.

This study is a Multi-Center, Randomized, Placebo-Controlled, Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer.

To date, the study has been opened at four ICORG sites; Waterford, Galway University, AMNCH Tallaght and Beaumont Hospitals. A further seven ICORG sites will be initiated in the coming weeks.

This study is being conducted in partnership with the Lineberger Comprehensive Cancer Research Center (LCCC) of the University of North Carolina.

Ireland is the only non-US country participating and ICORG’s accrual target is 100 out of the total 240 patients.

Leave a comment